Welcome
Support Centre
30 August 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Evaluation of internet cognitive behavioural therapy for insomnia disorder
ISRCTN ISRCTN44615689
DOI 10.1186/ISRCTN44615689
ClinicalTrials.gov identifier
EudraCT number
Public title Evaluation of internet cognitive behavioural therapy for insomnia disorder
Scientific title The comparative efficacy of online cognitive behavioural therapy (CBT) versus online imagery relief therapy (IRT) as treatments for insomnia disorder: a randomised placebo controlled trial
Acronym Sleepio
Serial number at source FM06509
Study hypothesis Online cognitive behavioural therapy (CBT) for adults with insomnia disorder will be associated with increased sleep efficiency at post treatment relative to a to a credible placebo intervention and a waiting list control condition
Lay summary Background and study aims:
This study was carried our to investigate if online cognitive behaviour therapy (CBT) given via the internet would be effective in the treatment of persistent insomnia. Insomnia is a very common problem, so providing treatment in this way could potentially reach many people who have problems sleeping. CBT is a non-drug treatment where people are helped to overcome the problem of the ‘racing mind’, and to establish a new healthy sleep pattern.

Who can participate?
Adults with persistent sleep problems, identified from their participation in the online Great British Sleep Survey.

What does the study involve?
People were randomly allocated to receive CBT, the standard treatment, or to a group that had to wait to receive treatment. In all groups information on sleep, mood and daytime functions (like energy and concentration) were gathered regularly so that we could evaluate the outcomes across the 6 weeks. They were then followed up 8 weeks later to see if benefits lasted. The online CBT was delivered by a virtual sleep expert (a cartoon character).

What are the possible benefits and risks of participating?
Benefits of participating included improvement in daytime wellbeing and in quality of sleep. There were no known risks associated with participating in the trial.

Where is the study run from?
The study was run online and there was no contact with participants except by email and through the web-based programme.

When is study starting and how long is it expected to run for?
The study ran from February to June 2011.

Who is funding the study?
Sleepio Ltd, London, UK

Who is the main contact?
Professor Colin Espie
colin@sleepio.com
Ethics approval University of Glasgow Faculty of Medicine Research Ethics Committee approved on the 20th August 2010
Study design Placebo controlled randomised trial
Countries of recruitment United Kingdom
Disease/condition/study domain Insomnia disorder
Participants - inclusion criteria 1. Healthy participants from the community at large (18+ years, either sex)
2. Completed the on-line Great British Sleep Survey (www.sleepio.com)
3. Meet proposed Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for insomnia disorder: complaint of poor sleep (difficulty initiating and/or maintaining sleep, early morning wakening, or non-restorative sleep), with daytime consequences for greater than or equal to 3 months
Participants - exclusion criteria 1. Possible significant mental (e.g. depression) or physical health problems (e.g. cardiovascular disease)
2. Disorders of sleep other than insomnia (e.g. sleep apnoea)
3. Dementia
4. Heavy alcohol use, excluded conservatively
5. Using online screening tools
Anticipated start date 01/03/2011
Anticipated end date 01/01/2012
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 156 (52 per condition)
Interventions This is a pragmatic, randomised controlled trial comprising three treatment arms:
1. Online cognitive behavioural therapy (CBT)
2. Online IRT (placebo)
3. Waiting list comprising usual care (treatment as usual [TAU])
2. Major assessments will be at baseline, post-treatment, and follow-up 6 weeks and 12 weeks later
3. All data will be analysed on an intention to treat basis
4. Participants randomised to the IRT placebo or TAU care arm will be offered CBT upon completion of the study.
5. CBT: is a 6 session treatment course guided by an animated personal therapist. It is both engaging and interactive and uses email, SMS technologies, and other motivational tools to prompt and support the user to progressively and systematically implement behavioural and cognitive strategies
6. The rationale given is that thoughts and behaviour influence engagement with sleep, sleep pattern and sleep quality, and subsequent daytime functioning
7. The programme provides effective strategies to deal with sleeplessness, to reduce dysfunctional sleep behaviour, attitudes and beliefs, and to help restore normal sleep patterns
8. The content of the therapy is based entirely upon proven methods, such as sleep hygiene education, relaxation, imagery, stimulus control, sleep restriction, cognitive restructuring and other cognitive techniques
9. Social networking methods will also be used to afford support to people undertaking the CBT programme
10. IRT: is also is a 6 session treatment, designed to mimic the structure and ethos of CBT but without any known therapeutic ingredient or advice on dealing with sleeplessness.
11. Thus non-specific factors such as credibility, expectation, regular sessions and support will be controlled
12. The rationale and instructions are based on a ‘quasi-desensitisation’ model
13. The participant constructs a list of chronologically ordered typical evening/bedtime activities and a list of 6 mental images
14. These are then paired with the hierarchy items in a pseudo-deconditioning paradigm 15. They are told that by using early evening regular practice they will become desensitised to their insomnia
16. The IRT placebo has been validated and found credible in numerous RCTs of ‘face to face’ individual and group CBT for insomnia over the past 25 years
17. TAU: is essentially a wait list control condition, where people complete all measures at the required times, and are entirely free to continue with whatever their usual care for insomnia is
18. Indeed, this much is true for all 3 conditions. So for example; GPs are free to prescribe/or not, unaffected by participation in the study
Primary outcome measure(s) 1. Sleep efficiency: this is the percentage of the time spend in bed that the person is asleep
2. Sleep Condition Indicator (SCI), a valid and reliable patient-reported outcome measure which is brief (8-item; range 0 - 32), valid (based on DSM-V) and reliable (a = 0.83). The SCI profiles daytime consequences of poor sleep and classifies clinical sleep status. Total
3. Derived sleep status category (very good, good, average, poor, very poor)
4. Measured at baseline, post-treatment evaluation and the 14 and 20 week follow-up evaluations
Secondary outcome measure(s) 1. Standard daily sleep diary data (e.g. sleep onset latency, wakeful time after sleep-onset)
2. Depression Anxiety and Stress Scales (DASS)
3. Sleep Disturbance Questionnaire (SDQ)
4. Content of Thoughts Inventory (CTI)
5. Sleep Effort Scale (SES)
6. Descriptive information on demographics and general physical and mental health, including alcohol use and lifestyle
7. CBT user experience and satisfaction
8. Adherence with treatment advice
9. Measured at baseline, post-treatment evaluation and the 14 and 20 week follow-up evaluations
Sources of funding Sleepio Ltd (UK)
Trial website https://www.sleepio.com/research/
Publications 1. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22654196
Contact name Prof  Colin  Espie
  Address University of Glasgow Sleep Centre
Sackler Institute of Psychobiological Research
Southern General Hospital
  City/town Glasgow
  Zip/Postcode G51 4TF
  Country United Kingdom
Sponsor University of Glasgow (UK)
  Address College of Medicine
Veterinary Medicine and Life Sciences
  City/town Glasgow
  Zip/Postcode G12 8QQ
  Country United Kingdom
  Email Sarah.Torbet@glasgow.ac.uk
  Sponsor website: http://www.gla.ac.uk/
Date applied 18/01/2011
Last edited 17/12/2012
Date ISRCTN assigned 18/05/2011
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.